-
Which of the various new formulations such as the new crown vaccine nasal spray will succeed?
Time of Update: 2021-04-14
This vaccine will be delivered as a nasal spray directly to the human respiratory tract, where the SARS-CoV-2 virus may invade and reproduce (the lungs and upper respiratory tract, etc.
In addition, vaccine components that use bacteria as carriers can deliver antigens directly to the mucosal tissues of the nose and oral cavity.
-
Yangtze River's leading chemical drug brand TOP10!
Time of Update: 2021-04-14
Sales of Anlotinib Capsules in Recent Years Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities Anlotinib Hydrochloride Capsules is a new class 1 anti-tumor drug developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of China Biopharmaceuticals.
-
Beijing Shuanglu Pharmaceutical Adefovir Dipivoxil Tablets Passed the Consistency Evaluation
Time of Update: 2021-04-14
In addition, for patients who develop resistance or poor response to lamivudine, telbivudine, or entecavir, adefovir dipivoxil can be added because adefovir does not have a cross-resistance site with the above 3 drugs Combination therapy.
-
What is the human intestinal micro-ecosystem, follow Yibeishi to see
Time of Update: 2021-04-14
This type of flora mainly helps our intestines to work in an orderly manner, inhibits the growth of harmful bacteria, maintains the intestinal balance, and protects human health.
Understand the human intestinal micro-ecology, and use lifespace probiotic solid beverages to better protect intestinal health.
-
The blockbuster policy of Chinese medicine is coming, and the entire chain of listed chains has become popular
Time of Update: 2021-04-14
Medical News, April 1st, 30th, the listed chain has an eye-catching performance in the capital market. As of today's close, Yixintang has risen as much as 8. 98%. This is the most obvious signal th
-
Hengrui Medicine Mycophenolate Sodium Enteric-coated Tablets Officially Approved
Time of Update: 2021-04-14
On March 31, the official website of NMPA showed that Chengdu Shengdi, a subsidiary of Hengrui Pharmaceuticals, was officially approved for mycophenolate sodium enteric-coated tablets, which became the first domestic imitation of the product.
According to the Insight database, only the original research company of mycophenolate sodium has been approved for listing in China.
-
The release of major Chinese medicine documents affects all pharmaceutical companies...
Time of Update: 2021-04-14
"Regulations" clearly, city development and reform, economic information, Chinese Medicine, the drug regulatory authorities shall take measures to support traditional Chinese medicine production enterprises commonly used in large-scale Chinese herbal medicines in the construction of authentic traditional Chinese medicine origin, standardization, industrialization of plant breeding base , Promote the use of fine varieties and improve the quality of Chinese medicinal materials.
-
Yangtze River acquires the right to develop and sell Daewoong Pharmaceutical's fexuprazan in China through a new 2.2 billion yuan agreement
Time of Update: 2021-04-14
According to the agreement, Haini Pharmaceuticals will be responsible for the clinical development of fexuprazan for the treatment of digestive system diseases, and will be responsible for the entire approval process of the drug in China.
-
Teresa's first-line treatment of NSLCL indications will be approved by medical insurance and will be approved for postoperative adjuvant treatment of lung cancer
Time of Update: 2021-04-14
In China, osimertinib was first approved by the NMPA in March 2017 for use in adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or after treatment with EGFR-TKIs, and have been tested to confirm the presence of EGFR T790M mutation-positive adult patients with locally advanced or metastatic NSCLC , The product name is Teresa, and it was included in the national medical insurance in 2018.
-
What are the ways to go to support domestically-made innovative drugs?
Time of Update: 2021-04-14
As a representative of the early domestic innovative drugs, the once-hot-selling antihypertensive compound reserpine and triamterene tablets (formerly known as Beijing Jiangya No.
-
Over 130 drugs were sold for weight loss, outsourcing and other main themes
Time of Update: 2021-04-14
Medical News, April 2nd. Multinational pharmaceutical companies are generally more practical. According to their own development strategies, they consciously divest some "old" non-profitable busine
-
The National Health Commission made it clear: encourage the production of reusable consumables
Time of Update: 2021-04-14
"Recommendations for the Catalog of Disposable Devices", the National Health Commission stated that the one-time use of high-value medical consumables may cause waste of resources, environmental pollution and rising medical costs.
-
Compaq's KHB-1802 project was suspended, can Langmu gain a foothold in the international market?
Time of Update: 2021-04-14
On the evening of March 28, Kanghong Pharmaceutical issued an announcement stating that the French National Agency for the Safety of Medicines and Health Products (hereinafter referred to as ANSM) has currently suspended "a multi-center, double-blind, randomized, dose range trial to evaluate conbercept eye The efficacy and safety of injection in the treatment of patients with neovascular age-related macular degeneration" Clinical Trial Project Trial 2 (KHB-1802).
-
Jimin Trust's New Coronary Neutralizing Antibody Obtains Clinical Approval from U.S. FDA
Time of Update: 2021-04-14
One of the key steps for the new coronavirus to infect human cells is the receptor binding domain (RBD) of the S1 subunit of the virus surface spike protein (S protein) and the angiotensin II converting enzyme 2 (ACE2) on the surface of human cells.
-
Medical representatives are difficult
Time of Update: 2021-04-14
Multi-party standardization of the practice of medical representativesTo a certain extent, the reduction of promotion costs by pharmaceutical companies has made it more difficult to carry out the work of medical representatives.
With the normalization of centralized procurement, the promotion costs of related products involving pharmaceutical companies are expected to be further reduced.
-
The latest news from pharmaceutical executives: Wang Rui joins Takeda China Yu Jinyi leaves Gilead
Time of Update: 2021-04-14
On June 15 last year, Yu Jinyi joined Gilead Sciences as the senior director of national sales for the hepatitis team, based in Shanghai.
-
The second batch of medical insurance key monitoring list is here!
Time of Update: 2021-04-14
Since Fujian Province has clearly strengthened the management of key monitoring drugs for medical insurance, two batches of lists have been issued one after another.
Since Fujian Province has clearly strengthened the management of key monitoring drugs for medical insurance, two batches of lists have been issued one after another.
-
State Council Information Office: Seven key tasks of Chinese medicine in the "14th Five-Year Plan"!
Time of Update: 2021-04-14
It is understood that during the "14th Five-Year Plan" period, multiple ministries and commissions at the national level will focus on inheriting the essence, maintaining integrity and innovation, deepening reform and improving the system as the driving force, insisting on giving full play to the characteristic advantages and multiple values of Chinese medicine, and insisting on highlighting Chinese medicine medical services The core value helps a healthy China.
-
A batch of drugs were investigated: Fengre Ganmao Granules, Ganmaoling Granules...
Time of Update: 2021-04-14
Jiangxi: Several commonly used drugs were investigated and punished Coincidentally, just a few days ago, the Jiangxi Provincial Food and Drug Administration issued the 2021 Phase 2 Drug Supervision Sampling Information Announcement (hereinafter referred to as the "Announcement").
-
Livzon's 1 billion varieties are super eye-catching, and the exclusive injection has increased by 600%!
Time of Update: 2021-04-14
Table 1: Livzon Group's preparation products with sales exceeding 100 million yuan in 2020 (unit: million yuan) Source: Company Annual Report In 2020, the company's sales revenue from multiple preparations showed a skyrocketing trend: the exclusive innovative drug ilaprazole successfully entered the 1 billion lineup, and sales revenue increased by 81.
